2026-01-10 - Analysis Report
Okay, here's a breakdown of the Recursion Pharmaceuticals (RXRX) analysis, based on the provided data, structured as requested.

**0. Report in English with Simple Numbers and Analysis**

**1. Return Rate Comparison**

*   **Ticker:** RXRX
*   **Company Name:** Recursion Pharmaceuticals Inc.
*   **Company Overview:** Recursion Pharmaceuticals is a clinical-stage biotechnology company decoding biology to discover, develop, and deliver impactful medicines.
*   **RXRX Cumulative Return:** -23.36%
*   **S&P 500 (VOO) Cumulative Return:** 41.59%
*   **Divergence:**
    *   Current: -71.3
    *   Relative Divergence: 2.4

**Analysis:** RXRX has significantly underperformed the S&P 500.  The stock has lost value while the S&P 500 has seen substantial gains. The relative divergence of 2.4 indicates RXRX is currently near the bottom of its historical divergence range compared to the S&P 500.

**Alpha, Beta Analysis**

|            | CAGR    | MDD    | Alpha    | Beta   | Cap(B) |
|------------|---------|--------|----------|--------|--------|
| 2022-2024  | 11.0%   | 55.8%  | -9.0%    | 2.3    | 3.5    |
| 2023-2025  | 9.0%    | 59.2%  | -53.0%   | 2.6    | 2.1    |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  Shows a moderate growth rate over both periods, but relatively low.
*   **MDD (Maximum Drawdown):**  Indicates significant potential losses.  The MDD is very high, suggesting high volatility and risk.
*   **Alpha:**  Negative Alpha in both periods means RXRX is underperforming relative to its risk-adjusted benchmark. It is performing far worse in the 2023-2025 timeframe.
*   **Beta:**  Beta greater than 1 indicates that RXRX is more volatile than the market.  The Beta is also relatively high, meaning that the stock is much more sensitive to market movements.
*   **Cap(B):** The market capitalization has decreased significantly between the periods.

**2. Recent Stock Price Fluctuations**

*   **Close:** 4.70
*   **Last Market Data:**
    *   Price: 4.66
    *   Previous Close: 4.70
    *   Change: -0.85%
*   **5-day SMA:** 4.536
*   **20-day SMA:** 4.394
*   **60-day SMA:** 4.8325

**Analysis:** The recent price (4.66) is below both the 60-day SMA (4.8325) and the previous close (4.70), indicating a recent downtrend. However, the price is above the 5-day SMA (4.536) and 20-day SMA (4.394), suggesting a possible short-term upward movement.

**3. Indicator Analysis**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 50.53
*   **PPO:** 1.54
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.70)
*   **Recent (20 days) relative divergence change:** 2.4 (+): 단기상승 (Short-term rise)
*   **Expected Return (%):** -218.4%

**Analysis:**

*   **MRI:** The MRI suggests a medium level of investment risk.
*   **RSI:**  The RSI is near 50, indicating neither overbought nor oversold conditions. It suggests a neutral momentum.
*   **PPO:** Positive PPO indicates short-term rising faster than long-term
*   **Hybrid Signal:** The signal suggests buying a portion of cash, but with caution due to the MRI.
*   **Divergence Change:** Recent relative divergence change indicates short-term increase.
*   **Expected Return:**  The very negative expected return is concerning and suggests significant downside risk if held long-term.

**4. Recent News & Significant Events**

*   **Positive REC-4881 Trial Data:** News of positive trial data for REC-4881 caused a surge in the stock price.
*   **Analyst Focus:** Rising analyst focus could indicate increased attention and potential for future upgrades or downgrades.
*   **Penny Stock Consideration:**  The mention of Recursion as a "fundamentally strong penny stock" suggests it's being considered by investors in that category.
*   **Analyst Upgrade:**  An analyst upgrade, like the one from JPMorgan, typically boosts investor confidence.
*   **Cathie Wood's Investment:** Cathie Wood's increased stake in Recursion can be seen as a positive signal, as she is a well-known investor.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (2.50 - ~Hold)
*   **Target Price:**
    *   Average: 7.00
    *   High: 11.00
    *   Low: 3.00
*   **Recent Rating Changes:** No data provided.

**Analysis:**

*   The analyst consensus is near "Hold," suggesting a neutral outlook, but the "Buy" indication is still shown.
*   The average target price ($7.00) is significantly higher than the current price ($4.66), implying potential upside. However, the wide range between the high ($11.00) and low ($3.00) target prices indicates uncertainty.

**5. Recent Earnings Analysis**

| 날짜        | EPS     | 매출    |
|-------------|---------|---------|
| 2025-11-05  | -0.36   | 0.01 B$ |
| 2025-08-05  | -0.41   | 0.02 B$ |
| 2025-05-05  | -0.5    | 0.01 B$ |
| 2024-11-06  | -0.34   | 0.03 B$ |
| 2025-11-05  | -0.34   | 0.03 B$ |

**Analysis:** Recursion is consistently reporting losses (negative EPS). While revenue fluctuates, it remains relatively low. The company is not yet profitable.

**6. Financial Information**

**Revenue and Profitability**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-09-30   | $0.00B   | -194.74%      |
| 2025-06-30   | $0.02B   | -5.54%        |
| 2025-03-31   | $0.01B   | -47.31%        |
| 2024-12-31   | $0.00B   | -183.62%      |
| 2024-09-30   | $0.03B   | 53.69%        |

**Capital and Profitability**

| Quarter      | Equity   | ROE       |
|--------------|----------|-----------|
| 2025-09-30   | $1.05B   | -15.50%   |
| 2025-06-30   | $0.92B   | -18.70%   |
| 2025-03-31   | $0.93B   | -21.68%   |
| 2024-12-31   | $1.03B   | -17.29%   |
| 2024-09-30   | $0.52B   | -18.27%   |

**Analysis:**

*   **Revenue:** Revenue is low and inconsistent. Some quarters show zero revenue.
*   **Profit Margin:**  Profit margins are largely negative, indicating the company is spending significantly more than it is earning.
*   **Equity:**  Equity is relatively high, indicating the company has a good capital base, but this can be due to capital funding of operations.
*   **ROE (Return on Equity):** Negative ROE values mean the company is not generating profits from shareholder investments.

**7. Comprehensive Analysis (Summary)**

Recursion Pharmaceuticals (RXRX) presents a mixed picture.

*   **Negative Performance:** RXRX has significantly underperformed the S&P 500.  Negative Alpha confirms this.
*   **High Risk:** High MDD and Beta indicate high volatility and market sensitivity.
*   **Unprofitable:** Consistent losses (negative EPS, negative profit margins, negative ROE) are a major concern.
*   **Positive Catalysts:** Recent positive trial data, analyst upgrades, and investment by Cathie Wood have provided short-term boosts to the stock price.
*   **Analyst Outlook:**  Analyst ratings are mixed.
*   **Technical Indicators:** The stock is showing some short-term bullish signs, but the long-term outlook is highly uncertain, given the negative expected return.
*   **Overall:** RXRX is a high-risk, high-reward investment. The company is in the biotechnology sector and developing medicines. If the company succeeds in development, the stock might yield high return.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.